circulatory drug | TEST DIRECTORY

TOP
drug test
circulatory drug

Laboratory：Hachioji

○circulatory drug

TEST NAME	SPECIMEN REQUIREMENT （ｍL）	CONTAINER	CAP COLOR	STORE TEMPERATURE (STABILITY)	TURNAROUND TIME (DAY)	METHODOLOGY	REFERENCE RANGE (UNIT)	BLOOD COLLECTION TIME
Digoxin	serum 0.5	S7P ↓ A00			2-4	EIA Enzyme immunoassay (EIA) EIA is based on the same assay principle as RIA. Using either enzyme-labeled antigen or antibody as a labeledsubstance, the antigen-antibody reaction is carried out. After adding a chromogenic substrate, the enzyme activity is measured.	Concentration of the elimination phase: 0.8-2.0 (ng/mL)	6 hours postdose-Immediately before the next administration(elimination phase)
Amiodarone	plasma 0.3	PH5 ↓ A00			3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	(ng/mL)	Immediately before the next administration(Trough concentration)
Bepridil	plasma 0.3	PH5 ↓ A00		（21 days）	3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	250-800 (ng/mL)
Aprindine	serum 0.3	S7P ↓ A00			3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	0.25-1.25 (μg/mL)	Oral:Immediately before the next administration(Trough concentration)Postdose2-4 hours (Peak concent
Aprindine	plasma 0.3	PH5 ↓ A00			3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	0.25-1.25 (μg/mL)	Oral:Immediately before the next administration(Trough concentration)Postdose2-4 hours (Peak concent
Disopyramide	serum 0.3	S7P ↓ A00			2-4	EIA Enzyme immunoassay (EIA) EIA is based on the same assay principle as RIA. Using either enzyme-labeled antigen or antibody as a labeledsubstance, the antigen-antibody reaction is carried out. After adding a chromogenic substrate, the enzyme activity is measured.	2.0-5.0 (μg/mL)	Immediately before the next administration(Trough concentration)
Disopyramide	plasma 0.3	PH5 ↓ A00			2-4	EIA Enzyme immunoassay (EIA) EIA is based on the same assay principle as RIA. Using either enzyme-labeled antigen or antibody as a labeledsubstance, the antigen-antibody reaction is carried out. After adding a chromogenic substrate, the enzyme activity is measured.	2.0-5.0 (μg/mL)	Immediately before the next administration(Trough concentration)
Lidocaine	serum 0.3	S7P ↓ A00			2-4	EIA Enzyme immunoassay (EIA) EIA is based on the same assay principle as RIA. Using either enzyme-labeled antigen or antibody as a labeledsubstance, the antigen-antibody reaction is carried out. After adding a chromogenic substrate, the enzyme activity is measured.	1.2-5.0 (μg/mL)	Intravenous:2 hours postdose Intravenous drip infusion:6-12 hours
Mexilethine	serum 0.3	S7P ↓ A00			3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	0.5-2.0 (μg/mL)	Oral:Immediately before the next administration(Trough concentration) Intravenous:Whenever necess
Procainamide	serum 0.4	S7P ↓ A00			2-4	EIA Enzyme immunoassay (EIA) EIA is based on the same assay principle as RIA. Using either enzyme-labeled antigen or antibody as a labeledsubstance, the antigen-antibody reaction is carried out. After adding a chromogenic substrate, the enzyme activity is measured.	4.0-10.0 (μg/mL)	Immediately before the next administration(Trough concentration)
Procainamide	plasma 0.4	PH5 ↓ A00			2-4	EIA Enzyme immunoassay (EIA) EIA is based on the same assay principle as RIA. Using either enzyme-labeled antigen or antibody as a labeledsubstance, the antigen-antibody reaction is carried out. After adding a chromogenic substrate, the enzyme activity is measured.	4.0-10.0 (μg/mL)	Immediately before the next administration(Trough concentration)
Propranolol	serum 0.3	S7P ↓ A00			4-10	HPLC High performance liquid chromatography (HPLC) A chromatography technique using a liquid mobile phase. HPLC separates a mixture into components promptly and accurately, using a column filled with a high-density absorbent and a high-pressure pump.	50-100 (ng/mL)	Immediately before the next administration(Trough concentration)
Propranolol	plasma 0.3	PH5 ↓ A00			4-10	HPLC High performance liquid chromatography (HPLC) A chromatography technique using a liquid mobile phase. HPLC separates a mixture into components promptly and accurately, using a column filled with a high-density absorbent and a high-pressure pump.	50-100 (ng/mL)	Immediately before the next administration(Trough concentration)
Pilsicainide	serum 0.3	S7P ↓ A00			3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	0.2-0.9 (μg/mL)	Immediately before the next administration(Trough concentration)
Pilsicainide	plasma 0.3	PH5 ↓ A00			3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	0.2-0.9 (μg/mL)	Immediately before the next administration(Trough concentration)
Propafenone	serum 0.3	S7P ↓ A00			3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	(ng/mL)
Cibenzoline	serum 0.3	S7P ↓ A00			3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	Trough concentration 70-250 (ng/mL)	Immediately before morning administration(Trough concentration)
Cibenzoline	plasma 0.3	PH5 ↓ A00			3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	Trough concentration 70-250 (ng/mL)	Immediately before morning administration(Trough concentration)
Pirmenol	plasma 1.3	PH5 ↓ A00			3-6	HPLC High performance liquid chromatography (HPLC) A chromatography technique using a liquid mobile phase. HPLC separates a mixture into components promptly and accurately, using a column filled with a high-density absorbent and a high-pressure pump.	400.0以上 (ng/mL)	Whenever necessary
Quinidine	serum 0.4	S7P ↓ A00			2-8	EIA Enzyme immunoassay (EIA) EIA is based on the same assay principle as RIA. Using either enzyme-labeled antigen or antibody as a labeledsubstance, the antigen-antibody reaction is carried out. After adding a chromogenic substrate, the enzyme activity is measured.	2.0-6.0 (μg/mL)	Immediately before the next administration(Trough concentration)
Quinidine	plasma 0.4	PH5 ↓ A00			2-8	EIA Enzyme immunoassay (EIA) EIA is based on the same assay principle as RIA. Using either enzyme-labeled antigen or antibody as a labeledsubstance, the antigen-antibody reaction is carried out. After adding a chromogenic substrate, the enzyme activity is measured.	2.0-6.0 (μg/mL)	Immediately before the next administration(Trough concentration)
Flecainide	serum 0.3	S7P ↓ A00			3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	200-1000 (ng/mL)	Immediately before the next administration(Trough concentration)
Flecainide	plasma 0.3	PH5 ↓ A00			3-5	LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) Liquid chromatography separates the target substance into compounds using difference in the affinity, which is combined with the mass spectrometry function that further divides the compounds by mass difference to isolate, fragment, and detect a specific mass ion.	200-1000 (ng/mL)	Immediately before the next administration(Trough concentration)

TEST DIRECTORY

○circulatory drug

Notifications of URL changes/lab information added

ラボを選択してください

Choose a laboratory

Notifications of URL changes/lab information added

Laboratory List

Advanced search